Sign Out
Pegfilgrastim (Neulastim) therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
Posology: One 6 mg dose (a single pre-filled syringe) of Pegfilgrastim (Neulastim) is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Paediatric population: The safety and efficacy of Pegfilgrastim (Neulastim) in children have not yet been established. Currently available data are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions but no recommendation on a posology can be made.
Patients with renal impairment: No dose change is recommended in patients with renal impairment, including those with end stage renal disease.
Method of administration: Pegfilgrastim (Neulastim) is injected subcutaneously. The injections should be given into the thigh, abdomen or upper arm. For instructions on handling of the medicinal product before administration, see Cautions of Usage.
Continue with Google